MedTrace Logo

Octaplas Adult TTP Trial

NCT01938404 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2019-10-14

No results posted yet for this study

Summary

To assess and evaluate the safety of octaplas™ in comparison to standard plasma product (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of thawing) used in the treatment of TTP, in patients undergoing Therapeutic Plasma Exchange, with a special emphasis on the occurrence of thromboembolic events (TEEs).

Conditions

  • Thrombotic Thrombocytopenic Purpura

Interventions

BIOLOGICAL

Octaplas

Octoplas infusion solution for IV administration

DRUG

Standard Plasma

Plasma given as replacement fluid

Sponsors & Collaborators

  • Octapharma

    lead INDUSTRY

Principal Investigators

  • Wolfgang Frenzel · International Medical Director

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-06
Primary Completion
2017-08-02
Completion
2017-08-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01938404 on ClinicalTrials.gov